Funder: International Myeloma Society
Due Dates: January 29, 2027, at 11:59 p.m. EST (Research proposal) | January 31, 2026 (2025–2026 cycle)
Funding Amounts: $175,000–$250,000 USD, including up to 8% institutional overhead; second-year funding may be considered
Summary: Supports investigator-initiated translational research in plasma cell disorders to improve prevention, detection, diagnosis, and treatment and pursue a cure for myeloma.
Key Information: The PI or Co-I should be an IMS member; previous awardees cannot apply with a different research proposal.
Description
The International Myeloma Society (IMS) and Paula and Rodger Riney Foundation support state-of-the-art, investigator-initiated translational research in plasma cell dyscrasias. The award seeks to improve prevention, early detection, diagnosis, and treatment of plasma cell disorders, with a focus on finding a cure for multiple myeloma. It also encourages collaboration between institutions.
Eligible research spans molecular assays, imaging techniques, drugs, biological agents, and other methodologies applicable to myeloma treatment, using cellular, molecular, structural, biochemical, or genetic approaches. Projects may advance toward clinical trials, prevention studies, early detection, treatment, or biomarker development. Reverse-translational work using human biospecimens to investigate phenomena, identify targets, and develop treatments is also supported. Projects must result in clinical translation and have the potential to change the current paradigm of myeloma management.
